Abbott Laboratories Exceeds Q2 Earnings Estimates, Raises FY26 Adjusted EPS Outlook

Abbott Laboratories reported better-than-expected results for the second quarter and raised its full-year 2026 adjusted earnings per share guidance. The company's performance was driven by strong revenue growth and operational efficiency.

By Meghavi Singh, SA News Editor · Seeking Alpha · July 16, 2026, 11:57 UTC

Tickers: $ABT

Topics: earnings healthcare pharmaceuticals

Read the full article at Seeking Alpha

More World news

Nvidia Shares Plunge Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:35 UTC
Jensen Huang Resigns as Nvidia CEO; Colette Kress Appointed Interim CEO TechCrunch · November 12, 2026, 15:37 UTC
Merck KGaA Raises 2026 Outlook Amid Pending Bio-Techne Acquisition Seeking Alpha · November 12, 2026, 15:31 UTC
Chinese AI Firms Seek Alternative Access to Nvidia Chips Amid Potential US Export Restrictions Seeking Alpha · November 12, 2026, 15:32 UTC
Purcell & Lefkowitz LLP Launches Shareholder Investigation into Dick's Sporting Goods PR Newswire · November 12, 2026, 15:34 UTC
Pomerantz Law Firm Investigates Fervo Energy Following Allegations of Securities Fraud PR Newswire · November 12, 2026, 15:35 UTC
Pomerantz Law Firm Investigates Boston Scientific Following Q3 Earnings Miss and Guidance Downgrade PR Newswire · November 12, 2026, 15:35 UTC
Jensen Huang Concludes 33-Year Tenure as CEO of Nvidia Seeking Alpha · November 12, 2026, 15:29 UTC
Metalla Royalty & Streaming Reports Q3 Revenue Growth and Increased Adjusted EBITDA Seeking Alpha · November 12, 2026, 15:26 UTC
Fed Governor Michael Barr Warns AI Market Concentration Could Drive Income Inequality Seeking Alpha · November 12, 2026, 15:27 UTC